IBRX Company Profile and Key Details

Q: Who are the executives of IBRX?

Dr. Barry J. Simon M.D.Chief Corporation Affairs Officer & DirectorMs. Helen LuuChief Commercial OfficerMr. Richard Gerald AdcockPres, Chief Executive Officer & DirectorDr. Leonard S. Sender M.D.Chief Operating OfficerDr. Hans Georg Klingemann M.D., Ph.D.Chief Science Officer of CellularDr. Patrick Soon-Shiong FACS, FRCS (C), M.Sc.Executive Chairman, Global Chief Scientific & Medical OfficerMs. Sarah SingletonChief Communications OfficerDr. Enrique Diloné Ph.D., RACChief Technology OfficerMr. Jason R. LiljestromGen. Counsel & Corporation Sec.Mr. David C. SachsChief Financial Officer, Principal Financial Officer & Principal Accounting OfficerDr. Patrick Soon-Shiong F.A.C.S., FACS, FRCS (C), M.Sc.Executive Chairman, Global Chief Scientific & Medical OfficerDr. Sandeep K. Reddy M.D.Chief Medical Officer

NASDAQ : IBRX

ImmunityBio

$7.23

-0.5062-6.54%

Open: 3:14 PM

60.61

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

ImmunityBio, Inc. (IBRX) stock declined over -6.54%, trading at $7.23 on NASDAQ, down from the previous close of $7.74. The stock opened at $7.64, fluctuating between $7.17 and $7.69 in the recent session.

Stock Snapshot

7.74

Prev. Close

7.58B

Market Cap

7.17

Day Low

-8.51

P/E Ratio

-0.85

EPS (TTM)

-0.59

Cash Flow per Share

7.64

Open

1.05B

Number of Shares

7.69

Day High

10.4%

Free Float in %

-0.87

Book Value

13.25M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 21, 2026	7.87	7.90	7.26	7.74	21.42M
May 20, 2026	8.42	8.64	8.04	8.05	24.73M
May 19, 2026	7.96	7.96	7.33	7.76	17.52M
May 18, 2026	8.34	8.53	7.74	8.00	13.01M
May 15, 2026	8.05	8.14	7.81	7.97	11.29M
May 14, 2026	8.24	8.42	7.92	8.15	9.34M
May 13, 2026	8.01	8.34	7.78	8.15	10.47M
May 12, 2026	7.97	8.22	7.85	8.12	9.87M
May 11, 2026	8.44	8.69	7.93	8.11	14.37M
May 08, 2026	7.88	8.56	7.58	8.51	16.01M
May 07, 2026	7.82	8.11	7.36	7.76	18.64M
May 06, 2026	7.70	8.39	7.67	8.38	19.52M
May 05, 2026	7.54	7.77	7.43	7.58	9.02M
May 04, 2026	7.11	7.62	7.05	7.43	11.67M
Apr 30, 2026	6.99	7.18	6.95	7.10	6.45M
Apr 29, 2026	6.93	6.98	6.73	6.96	8.91M
Apr 28, 2026	7.25	7.27	6.91	6.96	10.82M
Apr 27, 2026	7.36	7.50	7.06	7.29	11.02M
Apr 23, 2026	7.98	8.27	7.82	8.19	9.61M
Apr 22, 2026	8.27	8.38	7.75	8.07	11.33M

Contact Details

San Diego, CA 92121

United States

https://immunitybio.com 858 633 0300

About Company

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.

Stock Peers

ARGX

11.97+1.49%

argenx SE$816.22 REGN

-7.17-1.10%

Regeneron Pharmaceuticals, Inc.$642.59 UTHR

1.94+0.34%

United Therapeutics Corporation$565.87 MDGL

0.12+0.02%

Madrigal Pharmaceuticals, Inc.$513.59 VRTX

3.1+0.72%

Vertex Pharmaceuticals Incorporated$433.54 PRAX

14.95+4.45%

Praxis Precision Medicines, Inc.$350.56 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 KRYS

2.18+0.72%

Krystal Biotech, Inc.$304.23 ALNY

2.03+0.68%

Alnylam Pharmaceuticals, Inc.$300.51 ASND

6.17+2.56%

Ascendis Pharma A/S$247.51

Company Overview

ImmunityBio, Inc. (NASDAQ:IBRX) closed at $7.23 USD, losing -$0.51 (-6.59%) from the previous close of $7.74. The stock is currently mid-range between its 52-week high and low $1.95 and $12.43. With a market capitalization of about $7.57 billion, ImmunityBio, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.07). Key stats such as the average daily volume over the past year has been around 22.81 million shares, volume is running light vs its 52-week average. Headquartered in San Diego, CA, ImmunityBio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Richard Gerald Adcock, the company employs approximately 671 people and listed since July 28, 2015. ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases.

Technical Performance

IBRX has shown sold momentum, gaining 150.19% over the past week and 170.0% over the past quarter, though year-to-date performance is up 227.27%. Short-term trend indicators are bearishly aligned (SMA20 29.82%, SMA50 91.89%, SMA200 203.76%). The stock’s 14-day RSI is 65.08 (firm momentum), while the ATR of 1.19 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -23.17% below its high and over 421.86% above its low. Average 10-day trading volume of 14.71 million shares is below the 3-month average of 22.89 million, indicating normal recent market interest.

Valuation Metrics

ImmunityBio, Inc. trades at a P/E ratio of -9.06, slightly below the S&P 500 average, with a price-to-sales ratio of 56.02 and a price-to-book ratio of -8.9 indicating negative book value, which may reflect financial stress. The P/FCF stands at -26.42, also below market averages.

Dividend & Fair Value

ImmunityBio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$5.63. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

ImmunityBio, Inc. generated EPS of -$0.39 over the past year. Five-year average earnings growth is 15.6%. The latest quarter delivered EPS of -$0.62. The next quarter is forecast at -$0.08. Next year's EPS is expected at $26.88. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 34 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $30.00 to $7.00. The high target offers 287.6% upside. The low target suggests -9.56% downside. The mean target is $20.67. This offers 167.05% upside. ImmunityBio, Inc. earnings surprise history is a mixed track record. The quarter that ended May 07, 2026, missed forecasts by 675.0%. The prior quarter beat by -25.0%. Over the last six quarters, Apple has recorded several small beats. These include -42.31% in March 03, 2025.

Shareholding & Insider Activity

ImmunityBio, Inc. has 945.25 million shares outstanding. The public float is 193.56 million shares, elevated short interest at 26.48% of float. This equals 77.07 million shares. The short ratio is 10.42 days. Institutional investors hold 46.62% of the float. Insiders own 63.67%. Simon Barry J. holds 2.85 million shares, Thomas John C has 207.48 thousand shares and Cohen Cheryl has 200.62 thousand shares. Over the past six months, insider transactions show net selling. They sold 425.00 thousand shares across 7 transactions.

Financial & Profitability Overview

Over the trailing twelve months, ImmunityBio generated $622.00K in revenue, or $0.00 per share. Gross margin was -2876.21%, operating margin -58097.11%, and net profit margin -93761.41%. Returns are negative, with ROA at -115.61% and ROE at 99.35%.
On valuation metrics, ImmunityBio trades at a P/E of -9.06, P/S of 56.02 and P/B of -8.90. The current ratio is 6.67 and quick ratio is 6.66. Operationally, the company’s inventory turnover is 15.99 and cash conversion cycle is -332.06 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is -1.29, supported by a cash flow-to-debt ratio of -0.26.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, ImmunityBio posted revenue of $622.00K, down slightly from $240.00K in the prior quarter. Gross profit was - $17.89M (margin -2876.21%). Operating income was - $361.36M (margin -58097.1%). Net income was- $583.20M (EPS - $1.15).
The company ended the quarter with $266.46M in cash and short-term investments, a total debt of $883.68M, and net debt of $618.22M. Total assets were $504.45M, with equity of - $585.94M. Financials further reflected weakness, with operating cash flow of - $366.76M, free cash flow of - $397.34M, and capital expenditures of - $30.58M.

Price Forecast & Outlook

Our AI price prediction model suggests that ImmunityBio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.07%, with price expected at $8.21 by June 03, 2026, within a range of $7.74 to $8.66 3-Month Outlook: Projected rise of 35.27%, reaching $10.47 by August 19, 2026, with a range of $10.30 to $10.63. 1-Year Outlook: Projected gain of 376.1%, with price at $36.85 by May 21, 2027, within a range of $32.51 to $50.35.

Key Takeaways

ImmunityBio, Inc. (NASDAQ:IBRX) shares are up 227.27% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows ImmunityBio, Inc. trading at a premium to the broader market with a P/E of -9.06. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $21.21, suggesting 174.03% upside. Our AI forecast model points to short-term strength (6.07% over two weeks), a medium-term rise (35.27% over three months), and a longer-term gain (376.1% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current ImmunityBio, Inc. (IBRX) stock price?

ImmunityBio, Inc. (NASDAQ: IBRX) stock price is $7.23 in the last trading session. During the trading session, IBRX stock reached the peak price of $7.69 while $7.17 was the lowest point it dropped to. The percentage change in IBRX stock occurred in the recent session was -6.54% while the dollar amount for the price change in IBRX stock was - $0.51.

IBRX's industry and sector of operation?

The NASDAQ listed IBRX is part of Biotechnology industry that operates in the broader Healthcare sector. ImmunityBio, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of IBRX?

Dr. Barry J. Simon M.D.
Chief Corporation Affairs Officer & Director
Ms. Helen Luu
Chief Commercial Officer
Mr. Richard Gerald Adcock
Pres, Chief Executive Officer & Director
Dr. Leonard S. Sender M.D.
Chief Operating Officer
Dr. Hans Georg Klingemann M.D., Ph.D.
Chief Science Officer of Cellular
Dr. Patrick Soon-Shiong FACS, FRCS (C), M.Sc.
Executive Chairman, Global Chief Scientific & Medical Officer
Ms. Sarah Singleton
Chief Communications Officer
Dr. Enrique Diloné Ph.D., RAC
Chief Technology Officer
Mr. Jason R. Liljestrom
Gen. Counsel & Corporation Sec.
Mr. David C. Sachs
Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer
Dr. Patrick Soon-Shiong F.A.C.S., FACS, FRCS (C), M.Sc.
Executive Chairman, Global Chief Scientific & Medical Officer
Dr. Sandeep K. Reddy M.D.
Chief Medical Officer

How IBRX did perform over past 52-week?

IBRX's closing price is 296.92% higher than its 52-week low of $1.95 where as its distance from 52-week high of $12.43 is -37.73%.

How many employees does IBRX have?

Number of IBRX employees currently stands at 671.

Link for IBRX official website?

Official Website of IBRX is: https://immunitybio.com

How do I contact IBRX?

IBRX could be contacted at phone 858 633 0300 and can also be accessed through its website. IBRX operates from 3530 John Hopkins Court, San Diego, CA 92121, United States.

How many shares of IBRX are traded daily?

IBRX stock volume for the day was 13.25M shares. The average number of IBRX shares traded daily for last 3 months was 22.81M.

What is the market cap of IBRX currently?

The market value of IBRX currently stands at $7.58B with its latest stock price at $7.23 and 1.05B of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	671
Beta	0.06
Sales or Revenue	$622.00K
5Y Sales Change%	1.059%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

IBRX Company Profile and Key Details

ImmunityBio

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Dividend & Fair Value

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Valuation Metrics

Price Forecast & Outlook

Key Takeaways